IOL Chemicals and Pharmaceuticals · NSE: IOLCP · BSE: 524164
Q4 FY23 results · Jan–Mar 2023
IOL Chemicals and Pharmaceuticals reported revenue from operations of ₹587.21 crore (up 2.6% from Q4 FY22) and net profit of ₹64.78 crore (up 117.7% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 587.21 | 572.49 | +2.6% | 523.48 | +12.2% |
| Other income | 8.73 | 6.93 | +26.0% | 6.65 | +31.3% |
| Total income | 595.94 | 579.42 | +2.9% | 530.13 | +12.4% |
| Profit before tax | 87.04 | 38.71 | +124.9% | 32.89 | +164.6% |
| Net profit for the period | 64.78 | 29.76 | +117.7% | 23.79 | +172.3% |
| EPS, basic (₹) | 11.03 | 5.07 | +117.6% | 4.05 | +172.3% |
| Net margin (%) | 11.0 | 5.2 | 4.5 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 587.21 | 572.49 | +2.6% | 523.48 | +12.2% |
| Other income | 8.72 | 6.93 | +25.8% | 6.64 | +31.3% |
| Total income | 595.93 | 579.42 | +2.8% | 530.12 | +12.4% |
| Profit before tax | 87.53 | 36.70 | +138.5% | 33.25 | +163.2% |
| Net profit for the period | 65.27 | 27.75 | +135.2% | 24.15 | +170.3% |
| EPS, basic (₹) | 11.11 | 4.73 | +134.9% | 4.12 | +169.7% |
| Net margin (%) | 11.1 | 4.8 | 4.6 |
Consolidated
- Filed with BSE
- 02 May 2023, 12:38 IST
- Board meeting
- 28 Apr 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 02 May 2023, 12:38 IST
- Board meeting
- 28 Apr 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE